Novartis Q4 Results

↓ ↑ Content Click below to navigate through the document Expected currency impact for Q1 and full year 2024 Company overview Financial review Conclusions Appendix References Currency impact vs. PY %pts, assuming late-January exchange rates prevail in 2024 FX impact on Net sales FX impact on Core operating income -1 -2 -2 -2 -3 -5 to -6 -7 -8 Q4 FY Q1 FY Q4 FY Q1 FY 2023 2024 2023 2024 Actual Simulation FINANCIAL PROFILE Q4 Core Oplnc FX impact includes app. -2%pts from the effect of mid Dec Argentina ARS devaluation¹ 1. Core results are non-IFRS measures as defined on page 49 of Condensed Financial Report. 2. IFRS requires for our Argentina subsidiary, as it operates in a hyperinflation economy, to translate for consolidation purposes their full year income statement to our USD presentation currency using the ARS closing rate, and not using the average exchange rate for the period. This results in the 9-months and the Q4 devaluation impact being recognized in Q4. □ NOVARTIS | Reimagining Medicine. Novartis Q4 Results | January 31, 2024 32

View entire presentation